Cytarabine Injection 2g/20mL (100mg/mL) Single Use Vial (SteriMax Inc., Canada)
Section 19A approved medicine
Cytarabine Injection 2g/20mL (100mg/mL) Single Use Vial (SteriMax Inc., Canada)
Section 19A approval holder
ORSPEC Pharma Pty Ltd ABN 15 634 980 417
Phone
02 4339 4239
Approved until
Status
Current
Medicines in short supply/unavailable
DBL CYTARABINE 2g/20mL injection vial - ARTG 47286
Indication(s)
Cytarabine may be used alone or in combination with other chemotherapeutic agents. It is indicated for induction of remission of leukaemia, particularly for acute myeloid leukaemia, in adults and children.
Cytarabine has been used for remission induction in acute lymphocytic leukaemia, chronic myeloid leukaemia and erythroleukaemia; and in the treatment and maintenance therapy of meningeal leukaemia.
Images
